Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELGN-2112 in preterm infants with intestinal malabsorption
NCT05670951Phase 3Recruiting
- Sponsor
- Elgan Pharma
- Start
- Feb 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elgn-gi in intestinal malabsorption, sponsored by Elgan Pharma. Started Feb 2025; status: recruiting.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorption
Beyond the preview
Go deeper on NCT05670951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05670951.